



Charles River Associates (CRA) Bolsters Life Sciences Practice with Appointment of Christopher Zealey as Vice President

October 6, 2026

BOSTON--(BUSINESS WIRE)--Oct. 6, 2026-- [Charles River Associates](#) (NASDAQ: CRAI), a worldwide leader in providing [economic, financial, and management consulting services](#), today announced the appointment of [Christopher Zealey](#) as a Vice President in the firm's [Life Sciences Practice](#).

"I am pleased to welcome Chris to CRA," said [Paul Maleh](#), President and Chief Executive Officer of Charles River Associates. "His areas of expertise include cross functional and medical strategic and tactical planning, insight generation, scientific communication strategy, and clinical positioning. He joins a team dedicated to addressing CRA's life sciences clients' most complex business challenges."

"Chris has an impressive track record of supporting [medical affairs](#) clients using clinical, stakeholder, and market insights to form actionable and measurable strategies," said [Dr. Gregory K. Bell](#), CRA Group Vice President and Life Sciences Practice Leader. "We look forward to working with Chris during an exciting period of growth and opportunity for our Practice and the broader industry. As clients face increasingly complex medical affairs and launch decisions, Chris's experience leveraging data, evidence, and stakeholder perspectives to inform strategy will further strengthen the value we bring to life sciences organizations."

As medical affairs continue to play an increasingly strategic role across the life sciences sector, CRA has expanded its capabilities to help clients navigate complex scientific, clinical, and stakeholder engagement challenges. The growing team of senior Life Sciences professionals brings deep experience across medical affairs strategy, enabling the company to deliver integrated solutions to life sciences organizations.

Before joining CRA, Mr. Zealey was a partner at a life sciences and pharmaceutical consulting firm where he led client engagements across the firm's consulting offerings, including strategic and tactical planning, healthcare professional and patient insight generation, strategic scientific narrative and platform development, and medical intelligence to support product launches and optimize in-line asset strategies.

Mr. Zealey holds a MSc in Biotechnology with a concentration in Business and Policy from McGill University and a BSc in Microbiology from the University of Waterloo.

About CRA's Life Sciences Practice

CRA's Life Sciences Practice works with leading biotech, medical device, and pharmaceutical companies; law firms; regulatory agencies; and national and international industry associations. We provide the analytical expertise and industry experience needed to address our clients' toughest issues. We have a reputation for rigorous and innovative analysis, careful attention to detail, and the ability to work effectively as part of a wider team of advisers.

About Charles River Associates (CRA)

Charles River Associates® is a leading global consulting firm specializing in [economic, financial, and management consulting services](#). CRA advises clients on economic and financial matters pertaining to litigation and regulatory proceedings, and guides corporations through critical business strategy and performance-related issues. Since 1965, clients have engaged CRA for its unique combination of functional expertise and industry knowledge, and for its objective solutions to complex problems. Headquartered in Boston, CRA has offices throughout the world. Detailed information about Charles River Associates, a registered trade name of CRA International, Inc., is available at www.crai.com. Follow us on [LinkedIn](#), [Instagram](#), and [Facebook](#).

SAFE HARBOR STATEMENT

Statements in this press release concerning the addition of Christopher Zealey, the expansion of CRA's Life Sciences Practice, and any future business Mr. Zealey may generate for CRA, are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management's current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors that could cause actual performance or results to differ materially from any forward-looking statements made by CRA include, among others: the failure to generate engagements for us; the potential loss of clients; the demand environment; global economic conditions; foreign exchange rate fluctuations; and intense competition. Additional potential factors that could affect our financial results are included in our periodic filings with the Securities and Exchange Commission, including those under the heading "Risk Factors." We cannot guarantee any future results, levels of activity, performance, or achievement. We undertake no obligation to update any forward-looking statements after the date of this press release, and we do not intend to do so.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20261006751406/en/>

Media Relations
CRA International
media@crai.com
416-825-1595

Nicholas Manganaro
Sharon Merrill Advisors
crai@investorrelations.com
617-542-5300

